Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review
Drug-induced liver injury (DILI) has become a serious public health problem. For the management of DILI, discontinuation of suspicious drug or medicine is the first step, but the treatments including drugs and supporting approaches are needed. Reference to clinical patterns and disease severity grad...
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado em: |
Frontiers Media S.A.
2022-01-01
|
| Colecção: | Frontiers in Pharmacology |
| Assuntos: | |
| Acesso em linha: | https://www.frontiersin.org/articles/10.3389/fphar.2021.806249/full |
| _version_ | 1828146076245295104 |
|---|---|
| author | Meng Li Qiong Luo Yanyan Tao Xin Sun Xin Sun Chenghai Liu Chenghai Liu Chenghai Liu Chenghai Liu |
| author_facet | Meng Li Qiong Luo Yanyan Tao Xin Sun Xin Sun Chenghai Liu Chenghai Liu Chenghai Liu Chenghai Liu |
| author_sort | Meng Li |
| collection | DOAJ |
| description | Drug-induced liver injury (DILI) has become a serious public health problem. For the management of DILI, discontinuation of suspicious drug or medicine is the first step, but the treatments including drugs and supporting approaches are needed. Reference to clinical patterns and disease severity grades of DILI, the treatment drugs were considered to summarize into hepatoprotective drugs (N-acetylcysteine and Glutathione, Glycyrrhizin acid preparation, Polyene phosphatidylcholine, Bicyclol, Silymarin), anticholestatic drug (Ursodeoxycholic acid, S-adenosylmethionine, Cholestyramine), immunosuppressants (Glucocorticoids) and specific treatment agents (L-carnitine, Anticoagulants). The current article reviewed the accumulated literature with evidence-based medicine researches for DILI in clinical practice. Also the drawbacks of the clinical studies involved in the article, unmet needs and prospective development for DILI therapy were discussed. |
| first_indexed | 2024-04-11T20:41:50Z |
| format | Article |
| id | doaj.art-901b8ade1ccd416fad1d57c7c2bb2483 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-11T20:41:50Z |
| publishDate | 2022-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-901b8ade1ccd416fad1d57c7c2bb24832022-12-22T04:04:11ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-01-011210.3389/fphar.2021.806249806249Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature ReviewMeng Li0Qiong Luo1Yanyan Tao2Xin Sun3Xin Sun4Chenghai Liu5Chenghai Liu6Chenghai Liu7Chenghai Liu8Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaInstitute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaInstitute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaInstitute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaShanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai, ChinaInstitute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaShanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai, ChinaKey Laboratory of Liver and Kidney Diseases, Ministry of Education, Shanghai, ChinaShanghai Innovation Center of TCM Health Service, Shanghai, ChinaDrug-induced liver injury (DILI) has become a serious public health problem. For the management of DILI, discontinuation of suspicious drug or medicine is the first step, but the treatments including drugs and supporting approaches are needed. Reference to clinical patterns and disease severity grades of DILI, the treatment drugs were considered to summarize into hepatoprotective drugs (N-acetylcysteine and Glutathione, Glycyrrhizin acid preparation, Polyene phosphatidylcholine, Bicyclol, Silymarin), anticholestatic drug (Ursodeoxycholic acid, S-adenosylmethionine, Cholestyramine), immunosuppressants (Glucocorticoids) and specific treatment agents (L-carnitine, Anticoagulants). The current article reviewed the accumulated literature with evidence-based medicine researches for DILI in clinical practice. Also the drawbacks of the clinical studies involved in the article, unmet needs and prospective development for DILI therapy were discussed.https://www.frontiersin.org/articles/10.3389/fphar.2021.806249/fulldrug-induced liver injuryacute liver failurepharmacotherapyhepatoprotective druganticholestatic drug |
| spellingShingle | Meng Li Qiong Luo Yanyan Tao Xin Sun Xin Sun Chenghai Liu Chenghai Liu Chenghai Liu Chenghai Liu Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review Frontiers in Pharmacology drug-induced liver injury acute liver failure pharmacotherapy hepatoprotective drug anticholestatic drug |
| title | Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review |
| title_full | Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review |
| title_fullStr | Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review |
| title_full_unstemmed | Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review |
| title_short | Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review |
| title_sort | pharmacotherapies for drug induced liver injury a current literature review |
| topic | drug-induced liver injury acute liver failure pharmacotherapy hepatoprotective drug anticholestatic drug |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2021.806249/full |
| work_keys_str_mv | AT mengli pharmacotherapiesfordruginducedliverinjuryacurrentliteraturereview AT qiongluo pharmacotherapiesfordruginducedliverinjuryacurrentliteraturereview AT yanyantao pharmacotherapiesfordruginducedliverinjuryacurrentliteraturereview AT xinsun pharmacotherapiesfordruginducedliverinjuryacurrentliteraturereview AT xinsun pharmacotherapiesfordruginducedliverinjuryacurrentliteraturereview AT chenghailiu pharmacotherapiesfordruginducedliverinjuryacurrentliteraturereview AT chenghailiu pharmacotherapiesfordruginducedliverinjuryacurrentliteraturereview AT chenghailiu pharmacotherapiesfordruginducedliverinjuryacurrentliteraturereview AT chenghailiu pharmacotherapiesfordruginducedliverinjuryacurrentliteraturereview |